Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.9 pts more than Nifty Microcap 250 and 15.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shree Ganesh Remedies reported flat revenue at Rs 10,929 lakhs for FY26 vs Rs 10,860 lakhs in FY25, with PAT declining 23% to Rs 1,777 lakhs from Rs 2,310 lakhs. The Q4 FY26 showed strong revenue growth of 36% YoY to Rs 3,320 lakhs, but full-year profitability was impacted by a 71% increase in finance costs (Rs 207 lakhs to Rs 356 lakhs) and compressed margins. EPS fell from Rs 17.98 to Rs 13.84. The company operates in API intermediates and speciality chemicals. The auditors issued unmodified (clean) opinions on both standalone and consolidated financial results. The company also reappointed S N D K & Associates LLP as internal auditors for FY27.
The 23% decline in annual PAT despite flat revenue signals margin compression due to higher borrowing costs, which could concern investors. However, the clean audit opinion and strong operating cash flow of Rs 2,375 lakhs are reassuring signs for financial stability.